<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) are a group of stem cell disorders characterized by <z:mpath ids='MPATH_589'>dysplasia</z:mpath> of one or more hematopoietic cell lineages and a risk of progression to <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The <z:chebi fb="0" ids="17562">cytidine</z:chebi> analog <z:chebi fb="0" ids="2038">azacitidine</z:chebi> (Vidaza), a hypomethylating agent, improves survival in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, but its mechanism of action is not well understood </plain></SENT>
<SENT sid="2" pm="."><plain>MATERIALS AND METHODS: The effects of <z:chebi fb="0" ids="2038">azacitidine</z:chebi> on the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-derived cell line SKM-1 were investigated by DNA methylation assay, cell proliferation assay, and a subcutaneous xenograft mouse model </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: <z:chebi fb="0" ids="2038">Azacitidine</z:chebi> and <z:chebi fb="0" ids="50131">decitabine</z:chebi> induced hypomethylation of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor gene cyclin-dependent kinase 4 inhibitor B (CDKN2B) in SKM-1 cells, whereas the deoxycytidine analog <z:chebi fb="0" ids="28680">cytarabine</z:chebi> did not </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="2038">Azacitidine</z:chebi> and <z:chebi fb="0" ids="50131">decitabine</z:chebi> also inhibited SKM-1 cell growth in vitro </plain></SENT>
<SENT sid="5" pm="."><plain>In the mouse <z:e sem="disease" ids="C1520166" disease_type="Experimental Model of Disease" abbrv="">xenograft model</z:e>, <z:chebi fb="0" ids="2038">azacitidine</z:chebi> significantly suppressed <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSION: Inhibition of DNA methyltransferase by <z:chebi fb="0" ids="2038">azacitidine</z:chebi> contributes to its antiproliferative and antitumor effects against SKM-1 cells and may explain its clinical efficacy in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>